All 1 tracked stories fall under one category: market-trends. HMI-115 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 7, the average consequence score sits above the same-window beat average of 6.6. They are less corroborated than the beat average, carrying 3 original sources each against 3.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Bayer
All 1 tracked stories fall under one category: market-trends. HMI-115 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 7, the average consequence score sits above the same-window beat average of 6.6. They are less corroborated than the beat average, carrying 3 original sources each against 3.3 for the same window. Bayer appears in 1 tracked Healthcare story from March 25, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Bayer. Shared-story counts are live from our verified record — not editorial picks.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.